» Articles » PMID: 20009134

NASH and Cryptogenic Cirrhosis: a Histological Analysis

Overview
Journal Ann Hepatol
Specialty Gastroenterology
Date 2009 Dec 17
PMID 20009134
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Epidemiological studies indicate that nonalcoholic steatohepatitis (NASH) is a common cause of cirrhosis described as 'cryptogenic'. To address this from a histological perspective and to examine the significance of residual histological findings as an indication of prior NASH, we looked back at biopsies in patients who presented with cirrhosis without sufficient histological features to diagnose NASH but who had prior histologically confirmed non-cirrhotic NASH.

Methods: Seven patients were identified with biopsy pairs showing non-specific (cryptogenic) cirrhosis in the latest specimen and a prior biopsy showing non-cirrhotic NASH. Using an expanded NASH-CRN system scored blindly by light microscopy, we compared the early and late biopsies to each other and to a cohort of 13 patients with cirrhosis due to hepatitis C without co-existing metabolic syndrome.

Results: Macrosteatosis, although uniformly present in the non-cirrhotic NASH specimens, declined in the late stage cirrhotic NASH specimens and was not useful in the distinction of late cirrhotic NASH from cirrhotic viral hepatitis. However, the presence of ballooned cells, Mallory-Denk bodies, and megamitochondria and the absence of apoptotic bodies were significantly different in late stage cirrhotic NASH compared to cirrhosis due to hepatitis C.

Conclusions: Histologically advanced NASH presenting as non-specific or cryptogenic cirrhosis has residual changes which are consistent with prior steatohepatitis but which differ from cirrhosis due to hepatitis C. These results provide histological support for the more established epidemiological associations of NASH with cryptogenic cirrhosis and for criteria used in several proposed classifications of cryptogenic cirrhosis.

Citing Articles

Antiplatelet Prophylaxis Reduces the Risk of Early Hepatic Artery Thrombosis Following Liver Transplantation in High-Risk Patients.

Minciuna I, De Jonge J, Den Hoed C, Maan R, Polak W, Porte R Transpl Int. 2025; 37:13440.

PMID: 39744042 PMC: 11692146. DOI: 10.3389/ti.2024.13440.


NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.

Sergi C Int J Mol Sci. 2024; 25(15).

PMID: 39126031 PMC: 11313354. DOI: 10.3390/ijms25158462.


Development of fatty liver disease model using high cholesterol and low choline diet in white leghorn chickens.

Yadav K, Boley P, Khatiwada S, Lee C, Bhandari M, Kenney S Vet Res Commun. 2024; 48(4):2489-2497.

PMID: 38861204 PMC: 11315703. DOI: 10.1007/s11259-024-10420-1.


Primary Care Utilization, Preventative Screening, and Control of Metabolic Syndrome in Metabolic Dysfunction-Associated Steatohepatitis Liver Transplant Recipients.

Flynn S, Saxena V, Brandman D J Prim Care Community Health. 2024; 15:21501319241247974.

PMID: 38650519 PMC: 11036922. DOI: 10.1177/21501319241247974.


Development of Clinical Algorithm Utilizing Vibration-Controlled Transient Elastography to Detect Advanced Hepatic Fibrosis in Liver Transplant Recipients.

Arshad T, Vainer D, Khan H, Baral A, Garg S, Ang A Dig Dis Sci. 2024; 69(5):1844-1851.

PMID: 38499735 PMC: 11098731. DOI: 10.1007/s10620-024-08366-0.


References
1.
Ayata G, Gordon F, Lewis W, Pomfret E, Pomposelli J, Jenkins R . Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol. 2002; 33(11):1098-104. DOI: 10.1053/hupa.2002.129419. View

2.
Poonawala A, Nair S, Thuluvath P . Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology. 2000; 32(4 Pt 1):689-92. DOI: 10.1053/jhep.2000.17894. View

3.
Contos M, Cales W, Sterling R, Luketic V, Shiffman M, Mills A . Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl. 2001; 7(4):363-73. DOI: 10.1053/jlts.2001.23011. View

4.
Heneghan M, Zolfino T, Muiesan P, Portmann B, Rela M, Heaton N . An evaluation of long-term outcomes after liver transplantation for cryptogenic cirrhosis. Liver Transpl. 2003; 9(9):921-8. DOI: 10.1053/jlts.2003.50165. View

5.
Bacon B, Farahvash M, Janney C, Neuschwander-Tetri B . Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994; 107(4):1103-9. DOI: 10.1016/0016-5085(94)90235-6. View